Publications by authors named "Papatheodoridis G"

Background: Neuroendocrine neoplasms (NEN) are rare tumors arising from neuroendocrine cells most commonly in the gastrointestinal-tract. In recent years, advancements in therapeutics have increased survival rates in patients with NEN leading to a greater clinical burden compared to the general population.

Methods: The aim of this single-center case-control study was to investigate the incidence of low bone mass and changes in body composition in adult patients diagnosed with gastroenteropancreatic neuroendocrine tumors (GEPNET).

View Article and Find Full Text PDF

Background & Aims: Lipoprotein(a) (Lp(a)) is an emerging biomarker for cardiometabolic factors. We studied the role of Lp(a) in the full spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD).

Methods: Three independent analyses were implemented using a multi-center, cross-sectional, liver biopsy-based study (n = 332) (Study 1) and the UK Biobank prospective study (n = 270,004) (Study 2; median follow-up, 12.

View Article and Find Full Text PDF

Background: Acute kidney injury (AKI) represents a commonly seen condition in the natural course of cirrhosis associated with unfavourable outcomes.

Aims: To evaluate and compare the pooled mortality rates of patients with cirrhosis, with versus without AKI, across different clinical settings and diagnostic criteria.

Methods: A systematic search of several databases was performed up to Oct 2023.

View Article and Find Full Text PDF

Background: Patients with cirrhosis and portal hypertension may have alterations in intestinal barrier resulting in increased susceptibility for infections. We investigated the effect of propranolol in gastrointestinal motility, permeability and bacterial overgrowth in cirrhosis.

Methods: Patients with cirrhosis and esophageal varices were studied before and after a build-up dose of propranolol according to standard guidelines.

View Article and Find Full Text PDF

Autoimmune hepatitis (AIH) is a rare liver disease, of unknown origin, characterized by considerable heterogeneity. AIH can affect both sexes, of all ages, ethnicities and races. The revised Clinical Practice Guidelines (CPGs) of the Hellenic Association for the Study of the Liver aim to provide updated guidance to clinicians.

View Article and Find Full Text PDF
Article Synopsis
  • Recent studies on growth differentiation factor 15 (GDF-15) and interleukin-6 (IL-6) in inflammatory bowel diseases (IBD) are limited, prompting this assessment of their serum levels in patients with Crohn's disease (CD) and ulcerative colitis (UC).
  • The study involved 122 CD patients, 71 UC patients, and 44 healthy controls, revealing that elevated GDF-15 and IL-6 levels in active CD were significantly associated with various patient characteristics, including CRP levels and hospitalization rates.
  • In UC, while both GDF-15 and IL-6 were higher in active patients compared to controls, only IL-6 showed consistent associations with disease activity,
View Article and Find Full Text PDF

Background & Aims: The available literature on the effect of apolipoprotein C-III (ApoC-III) inhibition in MASLD reveals inconsistencies. The aim of the present work was to examine levels of ApoC-III in the entire spectrum of metabolic-dysfunction associated steatotic liver disease (MASLD).

Methods: This is a multicenter study involving patients enrolled in two gastroenterology-hepatology clinics (Greece and Australia) and in a bariatric-metabolic surgery clinic (Italy), with liver biopsy before and after bariatric surgery or lifestyle modification.

View Article and Find Full Text PDF

Background: Inflammatory bowel disease (IBD) commonly affects patients of reproductive age. The effect of disease activity on the outcome of pregnancy and its impact on neonatal health are areas of intense research.

Methods: Α national retrospective study of pregnancies in women with IBD between 2010 and 2020 was carried out in 22 IBD reference centers in Greece.

View Article and Find Full Text PDF

Long-term nucleos(t)ide analogue (Nuc) therapy in chronic hepatitis B (CHB) may lead to hepatitis B virus (HBV) suppression, alanine aminotransferase (ALT) normalization, improvement of histological lesions, and prevention of liver disease progression, but rarely achieve HBsAg loss, the hallmark of functional cure. HBeAg-negative CHB patients have often been recommended to continue Nuc therapy until HBsAg loss, which usually means indefinitely. However, long-term/life-long Nuc therapy is associated with increasing costs and concerns of adverse outcomes subsequent to poor adherence and/or self-cessation/loss-to-follow-up.

View Article and Find Full Text PDF

Background: Despite its high prevalence and impact on health, metabolic dysfunction-associated steatotic liver disease (MASLD) is inadequately addressed in European primary care (PC), with a large proportion of cases going undiagnosed or diagnosed too late. A multi-country European research consortium led a project to design and evaluate a patient-centered, integrated model for MASLD screening, diagnosis, and linkage to specialty care for European PC settings. Based on the lessons from this project, the latest research evidence, and existing guidelines for the management of MASLD, we sought to develop a set of practice recommendations for screening, referral, and management of MASLD in PC.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with inflammatory bowel disease (IBD) are at a higher risk for hepatitis B virus (HBV) and should ideally be vaccinated; this study evaluated the effectiveness of HBV vaccination among these patients and factors influencing their immune response.
  • A total of 409 IBD patients were studied, with 66.7% responding to the initial vaccination; those with lower body mass index had better immune responses, while certain disease types and treatments negatively impacted response rates.
  • Among nonresponders receiving revaccination, 58.3% achieved protective antibody levels, indicating that enhanced revaccination could benefit about half of these patients despite overall lower responsiveness compared to the general population.
View Article and Find Full Text PDF

Introduction: Dysphagia and bolus impaction are the cardinal manifestations of eosinophilic esophagitis (EoE). Esophageal biopsy sampling is mandatory for EoE diagnosis, data though suggest that clinician do not always obtain biopsies from patients with cardinal EoE symptoms during upper gastrointestinal endoscopy even if no other entity than EoE can explain patients symptoms. We aimed to search for the esophageal biopsy procurement rate as also for factors that drive clinicians to obtain esophageal biopsies among patients with cardinal EoE symptoms.

View Article and Find Full Text PDF

Introduction: Acute kidney injury (AKI) is a commonly seen condition in the natural course of cirrhosis. The aim of this study was to evaluate the pooled incidence and risk factors of AKI in different clinical stages and situations in patients with cirrhosis.

Methods: Search was conducted on 13 December 2023 across MEDLINE (PubMed), Embase, and Cochrane databases.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the accuracy of Agile scores (Agile 3+ and Agile 4) for diagnosing advanced liver fibrosis and cirrhosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and chronic hepatitis B or C (CHB/C).
  • It included 4,243 patients and found that Agile scores had diagnostic accuracy comparable to liver stiffness measurements (LSM) in MASLD and ALD, but performed less effectively in CHB/C.
  • The results suggest that using Agile scores alongside existing biomarkers like FIB-4 can improve diagnosis by reducing indeterminate results and enhancing specificity for advanced liver conditions.
View Article and Find Full Text PDF

One of the World Health Organization's targets for the 2030 viral hepatitis elimination strategy is to reduce new hepatitis C (HCV) infections. In Athens, Greece, people who inject drugs (PWID) have a high HCV prevalence, with increasing trends since the 2000s. This analysis aims to assess primary HCV incidence among PWID during 2012-2020.

View Article and Find Full Text PDF

Background: Preventing disease progression and viral suppression are the main goals of antiviral therapy in chronic hepatitis B (CHB). Liver stiffness measurement (LSM) by transient elastography is a reliable non-invasive method to assess liver fibrosis in patients with CHB. Our aim was to explore factors that may affect changes in LSMs during long term tenofovir (TDF) monotherapy in a well characterized cohort of patients with compensated CHB.

View Article and Find Full Text PDF

Background: The use of nucleos(t)ide analogs (NAs) with a high genetic barrier to resistance, namely entecavir and tenofovir, has improved the efficacy of antiviral prophylaxis against hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, the optimal duration and dosage of hepatitis B immunoglobulin (HBIG) administration, particularly in patients transplanted for HBV and hepatitis D virus (HDV) coinfection, remains controversial.

Methods: We evaluated 28 patients transplanted for HBV/HDV cirrhosis.

View Article and Find Full Text PDF

Introduction: Complete viral suppression with nucleos(t)ide analogs (NAs) has led to a profound reduction in hepatocellular carcinoma and mortality among patients with chronic hepatitis B. Finite therapy yields higher rates of functional cure; however, initial hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) elevations are almost certain after treatment interruption. We aimed to analyze off-treatment outcomes beyond 12 months after NA cessation.

View Article and Find Full Text PDF

Background: The existing literature does not provide adequate guidance on the diagnosis and management of patients with nonspecific terminal ileitis, while data regarding the percentage of patients who ultimately develop Crohn's disease (CD) are scarce. We evaluated the prevalence and natural course of nonspecific terminal ileitis in patients who underwent colonoscopy during a 11-year period.

Methods: All patients with endoscopic findings of terminal ileitis and nonspecific histological findings were included.

View Article and Find Full Text PDF

Aims: Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) outcomes such as MASH (metabolic dysfunction associated steatohepatitis), fibrosis and cirrhosis are ordinarily determined by resource-intensive and invasive biopsies. We aim to show that routine clinical tests offer sufficient information to predict these endpoints.

Methods: Using the LITMUS Metacohort derived from the European NAFLD Registry, the largest MASLD dataset in Europe, we create three combinations of features which vary in degree of procurement including a 19-variable feature set that are attained through a routine clinical appointment or blood test.

View Article and Find Full Text PDF

Background: Mortality among people who inject drugs (PWID) is high, with overdose and HIV infection being the main causes of death. In Greece, there have been no data on mortality, and two HIV outbreaks have been recorded in this population in the past decade. In this study, we aim to estimate the all-cause crude mortality rate and the standardised mortality ratio in this population during 2018-2022.

View Article and Find Full Text PDF
Article Synopsis
  • Type 2 diabetes and liver cirrhosis often occur together, creating challenges in finding effective glucose-lowering medications for cirrhotic patients.
  • Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a promising option, working independently of insulin to lower blood sugar and showing benefits in liver function, especially in metabolic liver diseases.
  • These inhibitors might offer additional advantages beyond managing diabetes, such as heart protection, potentially aiding patients with decompensated cirrhosis even if they don't have diabetes.
View Article and Find Full Text PDF

Background And Aims: Thyroid axis is currently under investigation as a therapeutic target in metabolic dysfunction-associated steatotic liver disease (MASLD). Thyroid function was examined herein in the full spectrum of disease.

Methods: Subjects were recruited and had liver biopsies in two Gastroenterology-Hepatology Clinics (Greece and Australia) and one Bariatric-Metabolic Surgery Clinic (Italy).

View Article and Find Full Text PDF